QVA149

Background The current Global initiative for chronic Obstructive Lung Disease (GOLD) treatment strategy recommends the use of one… Expand

RATIONALE Current Global Initiative for Chronic Obstructive Lung Disease (GOLD) strategy recommends the combination of two long… Expand

INTRODUCTION QVA149 is a novel, inhaled, once-daily dual bronchodilator containing a fixed-dose combination of the long-acting β2… Expand

We investigated the efficacy and safety of dual bronchodilation with QVA149 versus its monocomponents indacaterol and… Expand

BACKGROUND We evaluated the effect of dual, longacting inhaled bronchodilator treatment on exacerbations in patients with severe… Expand

BACKGROUND QVA149 is an inhaled fixed-dose combination therapy under development for the treatment of chronic obstructive… Expand

We evaluated the effect of QVA149, a dual bronchodilator combining indacaterol and glycopyrronium, on direct patient-reported… Expand

BACKGROUND QVA149 is an inhaled, once-daily fixed-dose dual bronchodilator combination of the long-acting β2-agonist indacaterol… Expand

Introduction The BEACON study evaluated the efficacy and safety of QVA149, a once-daily dual bronchodilator containing a fixed… Expand

ABSTRACT This study assessed the cardiovascular safety of QVA149, an inhaled, once daily, bronchodilator combination containing… Expand